Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901952 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL17206691 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL9924419 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL9900852 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL9924161 | 0.93 | MCHR1 (0.37) | KCNQ3KCNQ2MCHR1ADRA2AADRA1A | |
| SCHEMBL9924439 | 0.91 | GRM5 (0.39) | KCNQ3KCNQ2GRM4 | |
| SCHEMBL9924422 | 0.90 | KCNQ3 (0.42) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL17206704 | 0.89 | CYP2D6 (0.37) | PDE4BPDE4DPDE4APDE4CCES1 | |
| SCHEMBL9924233 | 0.88 | KMT2A (0.49) | KCNQ3KCNQ2MCHR1HTR1AADRA2A | |
| SCHEMBL17206713 | 0.88 | CES1 (0.44) | KCNQ3KCNQ2ARPDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169199-B2 | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-20130331392-A1 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2013-12-12 | — | — | US | disclosed |
| EP-2648736-A2 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | Lycera Corporation (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012078867-A2 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331392-A1 | CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | KCNQ3 1575/4885KCNQ2 1309/4885MCHR1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.